Carcinoma, Non-Small-Cell Lung Clinical Trials in Philadelphia, Pennsylvania

8 studies are recruiting for carcinoma, non-small-cell lung in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

   The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia, Pennsylvania

   Locations

   418 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06119581 on ClinicalTrials.gov

2. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

   The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective th…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia, Pennsylvania

   Locations

   369 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06890598 on ClinicalTrials.gov

3. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

   The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Philadelphia VA Medical Center, Philadelphia, Pennsylvania

   Locations

   203 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06667076 on ClinicalTrials.gov

4. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

   The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is comp…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   43 in total

   Run by

   Johnson & Johnson Enterprise Innovation Inc.

   See if you can join NCT06667908 on ClinicalTrials.gov

5. KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

   The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania

   Locations

   46 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT04165070 on ClinicalTrials.gov

6. KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

   This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substu…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania

   Locations

   47 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT04165798 on ClinicalTrials.gov

7. A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

   The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   304 in total

   Run by

   AstraZeneca

   See if you can join NCT06868277 on ClinicalTrials.gov

8. A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

   The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   16 in total

   Run by

   Lantern Pharma Inc.

   See if you can join NCT05456256 on ClinicalTrials.gov